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Book Review/Science in the Media
Escape Velocity: Why the Prospect 
of Extreme Human Life Extension 
Matters Now
Aubrey D. N. J. de Grey
T
he biogerontologist David 
Sinclair and the bioethicist 
Leon Kass recently 
locked horns in a radio debate 
(http:⁄⁄www.theconnection.org/
shows/2004/01/20040106_b_main.
asp) on human life extension that 
was remarkable for one thing: on the 
key issue, Kass was right and Sinclair 
wrong. Sinclair suggested, as have 
other experts, including his mentor 
Lenny Guarente and the National 
Institute on Aging advisory council 
member Elizabeth Blackburn, that 
Kass and other bioconservatives 
are creating a false alarm about life 
extension, because only a modest (say, 
30%) increase in human life span is 
achievable by biomedical intervention, 
whereas Kass’s apprehensions concern 
extreme or indeﬁ  nite life extension. 
Kass retorted that science isn’t like 
that: modest success tends to place the 
bit between our teeth and can often 
result in advances far exceeding our 
expectations.
Coping with Methuselah consists of 
seven essays, mostly on the economics 
of life extension but also including one 
essay surveying the biology of aging and 
one on the ethics of life extension. The 
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economic issues addressed are wide 
ranging, including detailed analysis of 
the balance between wealth creation by 
the employed and wealth consumption 
in pensions and health care; most 
chapters focus on the United States, 
but the closing chapter discusses these 
issues in a global context. Each essay 
is followed by a short commentary 
by another distinguished author. 
Within their own scope, all of these 
contributions are highly informative 
and rigorous. Dishearteningly, 
however, all echo Sinclair’s views about 
the limited prospects for life extension 
in the coming decades. In my opinion, 
they make three distinct oversights.
The ﬁ  rst concerns current science. 
Sinclair and several other prominent 
gerontologists are presently seeking 
human therapies based on the 
long-standing observation that 
lifelong restriction of caloric intake 
considerably extends both the healthy 
and total life span of nearly all species 
in which it has been tried, including 
rodents and dogs. Drugs that elicit the 
gene expression changes that result 
from caloric restriction might, these 
workers assert, extend human life span 
by something approaching the same 
proportion as seen in rodents—20% 
is often predicted—without impacting 
quality of life, and even when 
administered starting in middle age. 
They assiduously stress, however, that 
anything beyond this degree of life 
extension is inconceivable.
I agree with these predictions in 
two respects: that the degree of life 
extension achieved by ﬁ  rst-generation 
drugs of this sort may well approach the 
(currently unknown) amount elicitable 
by caloric restriction itself in humans, 
and that it is unlikely to be much 
exceeded by later drugs that work the 
same way. In two other ways, however, I 
claim they are incorrect. The ﬁ  rst error 
is the assumption of proportionality: I 
have recently argued (de Grey 2004), 
from evolutionary considerations, 
that longer-lived species will show 
a smaller maximal proportional 
life-span extension in response to 
starvation, probably not much more 
than the same absolute increase seen 
in shorter-lived species. The second 
error is the assertion that no other 
type of intervention can do better. In 
concert with other colleagues whose 
areas of expertise span the relevant 
ﬁ  elds, I have described (de Grey et al. 
2002, 2004) a strategy built around the 
actual repair (not just retardation of 
accumulation) of age-related molecular 
and cellular damage—consisting of just 
seven major categories of ‘rejuvenation 
therapy’ (Table 1)—that appears 
technically feasible and, by its nature, 
is indeﬁ  nitely extensible to greater 
life spans without recourse to further 
conceptual breakthroughs.
The second oversight made both 
by the contributors to Coping with 
Methuselah and by other commentators 
is demographic. Life expectancy is 
typically deﬁ  ned in terms of what 
demographers call a period survival 
curve, which is a purely artiﬁ  cial 
construction derived from the 
proportions of those of each age 
at the start of a given year who die 
during that year. The ‘life expectancy’ 
of the ‘population’ thus described 
is that of a hypothetical population 
whose members live all their lives 
with the mortality risk at each age 
that the real people of that age 
experienced in the year of interest. 
The remaining life expectancy of 
someone aged N in that year is more 
than this life expectancy minus N for 
two reasons: one mathematical (what 
one actually wants, roughly, is the age 
to which the probability of survival 
is half that of survival to N) and one 
biomedical (mortality rates at each 
age, especially advanced ages, tend 
to fall with time). My spirits brieﬂ  y 
rose on reading Aaron and Harris’s 
explicit statement (p. 69) of the latter 
reason. Unfortunately, they didn’t 
discuss what would happen if age-
speciﬁ  c mortality rates fell by more 
than 2% per year. An interesting 
scenario was thus unexplored: that in 
which mortality rates fall so fast that 
people’s remaining (not merely total) 
Table 1. Strategies for Engineered Negligible Senescence
Type of Age-Related Damage Suggested In Proposed Repair (Or Obviation)
Cell loss, cell atrophy Brody 1955 Stem cells, growth factors, exercise (Rao and Mattson 2001)
Senescent/toxic cells Hayﬁ  ck 1965 Ablation of unwanted cells (Barzilai et al. 1999)
Nuclear mutations/epimutations 
(only cancer matters)
Szilard 1959, 
Cutler 1982
Whole-body interdiction of lengthening of telomeres 
(de Grey et al. 2004)
Mitochondrial mutations Harman 1972 Allotopic expression of 13 proteins (Manfredi et al. 2002)
Extracellular cross-links Monnier and 
Cerami 1981
AGE-breaking molecules (Kass et al. 2001)
Extracellular aggregates Alzheimer 1907 Immune-mediated phagocytosis (Schenk et al. 1999)
Lysosomal aggregates Strehler 1959 Transgenic microbial hydrolases (de Grey 2002)
The seven categories of accumulating molecular or cellular side effects of metabolism whose possible contribution to age-related mammalian physical or cognitive decline is 
an established school of thought within contemporary biogerontology, and the foreseeable therapies that can repair or obviate them.
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life expectancy increases with time. Is 
this unimaginably fast? Not at all: it is 
simply the ratio of the mortality rates 
at consecutive ages (in the same year) 
in the age range where most people 
die, which is only about 10% per year. 
I term this rate of reduction of age-
speciﬁ  c mortality risk ‘actuarial escape 
velocity’ (AEV), because an individual’s 
remaining life expectancy is affected 
by aging and by improvements in life-
extending therapy in a way qualitatively 
very similar to how the remaining life 
expectancy of someone jumping off a 
cliff is affected by, respectively, gravity 
and upward jet propulsion (Figure 1).
The escape velocity cusp is closer 
than you might guess. Since we are 
already so long lived, even a 30% 
increase in healthy life span will give 
the ﬁ  rst beneﬁ  ciaries of rejuvenation 
therapies another 20 years—an 
eternity in science—to beneﬁ  t 
from second-generation therapies 
that would give another 30%, and 
so on ad inﬁ  nitum. Thus, if ﬁ  rst-
generation rejuvenation therapies were 
universally available and this progress 
in developing rejuvenation therapy 
could be indeﬁ  nitely maintained, these 
advances would put us beyond AEV. 
Universal availability might be thought 
economically and sociopolitically 
implausible (though that conclusion 
may be premature, as I will summarise 
below), so it’s worth considering the 
same question in terms of life-span 
potential (the life span of the luckiest 
people). Figure 1 again illustrates 
this: those who get ﬁ  rst-generation 
therapies only just in time will in fact 
be unlikely to live more than 20–30 
years more than their parents, because 
they will spend many frail years with a 
short remaining life expectancy (i.e., a 
high risk of imminent death), whereas 
those only a little younger will never 
get that frail and will spend rather 
few years even in biological middle 
age. Quantitatively, what this means 
is that if a 10% per year decline of 
mortality rates at all ages is achieved 
and sustained indeﬁ  nitely, then the 
ﬁ  rst 1000-year-old is probably only 5–10 
years younger than the ﬁ  rst 150-year-
old.
The third oversight that I observe 
in contemporary commentaries on 
life extension, among which Coping 
with Methuselah is representative, is the 
most signiﬁ  cant because of its urgency. 
First-generation rejuvenation therapies, 
whenever they arrive, will surely 
build on a string of prior laboratory 
achievements. Those achievements, 
it seems to me, will have progressively 
worn down humanity’s evidently 
desperate determination to close its 
eyes to the prospect of defeating its 
foremost remaining scourge anytime 
soon. The problem (if we can call it 
that) is that this wearing-down may 
have been completed long before the 
rejuvenation therapies arrive. There 
will come an advance—probably a 
single laboratory result—that breaks 
the camel’s back and forces society 
to abandon that denial: to accept 
that the risk of getting one’s hopes 
up and seeing them dashed is now 
outweighed by the risk of missing the 
AEV boat by inaction. What will that 
result be? I think a conservative guess 
is a trebling of the remaining life span 
of mice of a long-lived strain that have 
reached two-thirds of their normal life 
span before treatment begins. This 
would possess what I claim are the key 
necessary features: a big life extension, 
in something furry and not congenitally 
sick, from treatment begun in middle 
age.
It is the prospect of AEV, of course, 
that makes this juncture so pivotal. 
It seems quite certain to me that the 
announcement of such mice will 
cause huge, essentially immediate, 
society-wide changes in lifestyle and 
expenditure choices—in a word, 
pandemonium—resulting from the 
anticipation that extreme human life 
extension might arrive soon enough 
to beneﬁ  t people already alive. We 
will probably not have effective 
rejuvenation therapies for humans for 
at least 25 years, and it could certainly 
be 100 years. But given the present 
status of the therapies listed in Table 1, 
we have, in my view, a high probability 
of reaching the mouse life extension 
milestone just described (which I call 
‘robust mouse rejuvenation’) within 
just ten years, given adequate and 
focused funding (perhaps $100 million 
per year). And nobody in Coping with 
Methuselah said so. This timeframe 
could be way off, of course, but as 
Wade notes (p. 57), big advances often 
occur much sooner than most experts 
expect. Even the most obvious of these 
lifestyle changes—greater expenditure 
on traditional medical care, avoidance 
of socially vital but risky professions—
could severely destabilise the global 
economy; those better versed in 
economics and sociology than I would 
doubtless be even more pessimistic 
about our ability to negotiate this 
period smoothly. Overpopulation, 
probably the most frequently cited 
drawback of curing aging, could not 
result for many decades, but the same 
cannot be said for breadth of access 
irrespective of ability to pay: in a post-
9/11 world, restricted availability of 
rejuvenation therapies resembling 
that seen today with AIDS drugs would 
invite violence on a scale that, shall we 
say, might be worth trying to avoid.
Am I, then, resigned to a future in 
which countless millions are denied 
many decades of life by our studied 
reluctance to plan ahead today? Not 
quite. The way out is pointed to in 
Lee and Tuljapurkar’s (1997) graph 
of the average wealth consumed 
DOI: 10.1371/journal.pbio.0020187.g002
Figure 1. Physical and Actuarial Escape Velocities
Remaining life expectancy follows a similar trajectory whether one walks off a cliff 
or merely ages: the time scales differ, but one’s prognosis worsens with time. Mild 
mitigation of this (whether by jet propulsion or by rejuvenation therapies) merely 
postpones the outcome, but sufﬁ  ciently aggressive intervention overcomes the force of 
gravity or frailty and increasingly distances the individual from a sticky end. Numbers 
denote plausible ages, at the time ﬁ  rst-generation rejuvenation therapies arrive, of 
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and generated by an individual as a 
function of age, reproduced in Coping 
with Methuselah (p. 143). Once AEV is 
achieved, there will be no going back: 
rejuvenation research will be intense 
forever thereafter and will anticipate 
and remedy the life-threatening 
degenerative changes appearing 
at newly achieved ages with ever-
increasing efﬁ  cacy and lead time. This 
will bring about the greatest economic 
change of all in society: the elimination 
of retirement beneﬁ  ts. Retirement 
beneﬁ  ts are for frail people, and there 
won’t be any frail people. The graph 
just mentioned amply illustrates how 
much wealth will be released by this. 
My hope, therefore, is that once policy 
makers begin to realise what’s coming 
they will factor in this eventual windfall 
and allocate sufﬁ  cient short-term 
resources to make the period of limited 
availability of rejuvenation therapies 
brief enough to prevent mayhem. This 
will, however, be possible only if such 
resources begin to be set aside long 
enough in advance—and we don’t 
know how long we have.  
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